PL3785733T3 - Kompozycja farmaceutyczna do leczenia autyzmu - Google Patents

Kompozycja farmaceutyczna do leczenia autyzmu

Info

Publication number
PL3785733T3
PL3785733T3 PL20195373T PL20195373T PL3785733T3 PL 3785733 T3 PL3785733 T3 PL 3785733T3 PL 20195373 T PL20195373 T PL 20195373T PL 20195373 T PL20195373 T PL 20195373T PL 3785733 T3 PL3785733 T3 PL 3785733T3
Authority
PL
Poland
Prior art keywords
autism
treatment
pharmaceutical composition
pharmaceutical
composition
Prior art date
Application number
PL20195373T
Other languages
English (en)
Inventor
Lynn DURHAM
Original Assignee
Stalicla S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stalicla S.A. filed Critical Stalicla S.A.
Publication of PL3785733T3 publication Critical patent/PL3785733T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/01Hydrocarbons
    • A61K31/015Hydrocarbons carbocyclic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/44221,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL20195373T 2017-11-06 2018-11-06 Kompozycja farmaceutyczna do leczenia autyzmu PL3785733T3 (pl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201762582141P 2017-11-06 2017-11-06
EP17200219 2017-11-06
US201862663647P 2018-04-27 2018-04-27
EP18169952 2018-04-27
EP20195373.4A EP3785733B1 (en) 2017-11-06 2018-11-06 Pharmaceutical composition for the treatment of autism
EP18204763.9A EP3498297B1 (en) 2017-11-06 2018-11-06 Pharmaceutical composition for the treatment of autism

Publications (1)

Publication Number Publication Date
PL3785733T3 true PL3785733T3 (pl) 2022-07-11

Family

ID=64023965

Family Applications (1)

Application Number Title Priority Date Filing Date
PL20195373T PL3785733T3 (pl) 2017-11-06 2018-11-06 Kompozycja farmaceutyczna do leczenia autyzmu

Country Status (11)

Country Link
US (3) US10940140B2 (pl)
EP (3) EP3785733B1 (pl)
JP (2) JP2019089755A (pl)
KR (1) KR102372678B1 (pl)
CN (2) CN109821019A (pl)
AU (1) AU2018260807B2 (pl)
BR (1) BR102018072757A2 (pl)
CA (1) CA3023014C (pl)
DK (1) DK3785733T3 (pl)
ES (2) ES2962383T3 (pl)
PL (1) PL3785733T3 (pl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3480597A1 (en) * 2017-11-06 2019-05-08 Stalicla S.A. Biomarker assay for use in monitoring autism
CA3023014C (en) * 2017-11-06 2023-09-26 Stalicla Sa Pharmaceutical composition for treatment of autism
GB201911603D0 (en) * 2019-08-14 2019-09-25 Healx Ltd Treatment
GB201912760D0 (en) * 2019-09-05 2019-10-23 Healx Ltd Treatment
US20210180130A1 (en) * 2019-12-13 2021-06-17 Seawire Consultoria e Comercio LDA Detection and treatment of autism spectrum disorders
EP3881842A1 (en) * 2020-03-19 2021-09-22 Stalicla S.A. Compositions for the treatment of autism spectrum disorder
CA3174413A1 (en) * 2020-04-06 2021-10-14 Yuichi Iwaki Methods of reducing plasma level of macrophage migratory inhibitory factor in patients with ibudilast
WO2022079302A1 (en) * 2020-10-16 2022-04-21 Purposeful Ike Compositions and uses thereof
EP4012414A1 (en) 2020-12-11 2022-06-15 Stalicla S.A. Diagnosis of autism spectrum disorder phenotype 1
CN113528650B (zh) * 2021-08-03 2022-03-08 长沙艾克曼生物科技有限公司 Tmp21基因的表达可以作为自闭症早期筛查、早期识别和症状严重程度预测的客观指标
US20240423952A1 (en) * 2021-11-15 2024-12-26 Ibagen Pharmaceuticals, Inc. Compositions and methods for treating congenital disorders
US20250073226A1 (en) * 2021-12-21 2025-03-06 Osaka Universtiy Use of opioid for treatment of autism spectrum disorders
WO2023198176A1 (en) * 2022-04-15 2023-10-19 Xinhua Hospital Affiliated To Shanghai Jiaotong University School Of Medicine Prediction of the treatment response to bumetanide in subject with autism spectrum disorder
CN114974571B (zh) * 2022-05-27 2023-03-24 浙江大学医学院附属儿童医院 多模态数据驱动的孤独症检测系统、设备及存储介质
CH721671A2 (de) * 2024-03-21 2025-09-30 Stalicla Sa Behandlung von Autismus-Spektrum-Störungen
CH721683A2 (de) * 2024-03-25 2025-09-30 Stalicla Sa Behandlung von ASD
JP7811965B2 (ja) * 2024-06-04 2026-02-06 株式会社トクヤマ シリコーン組成物およびポリシロキサン化合物
CN119386023A (zh) * 2024-10-25 2025-02-07 南方医科大学南方医院 地尔硫卓在制备治疗自闭症的药物中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410508B1 (en) 1998-10-07 2002-06-25 Med College Georgia Res Inst Glucose-dependent insulinotropic peptide for use as an osteotropic hormone
US20050282896A1 (en) * 2002-10-07 2005-12-22 The University Of Alberta Methods of cardioprotection using dichloroacetate in combination with an inotrope
CA2551169A1 (en) * 2002-12-23 2004-07-08 Global Cardiac Solutions Pty Ltd Organ preconditioning, arrest, protection, preservation and recovery
DE10325813B4 (de) * 2003-06-06 2007-12-20 Universitätsklinikum Freiburg Prophylaxe und/oder Therapie bei der portalen Hypertonie
EP2377530A3 (en) * 2005-10-21 2012-06-20 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
CA2655310A1 (en) * 2006-06-22 2008-05-29 Cv Therapeutics, Inc. Use of a2a adenosine receptor agonists in the treatment of ischemia
WO2008019106A1 (en) * 2006-08-04 2008-02-14 Artesian Therapeutics, Inc. Methods and compositions for the treatment of pulmonary hypertension using a combination of a calcium channel blocker and a phosphodiesterase inhibitor
MX2011007759A (es) * 2009-01-22 2011-10-11 Neurotherapeutics Pharma Inc Analogos de bumetanida, furosemida, piretanida, azosemida y torsemida, composiciones y metodos de uso.
JP2012532855A (ja) * 2009-07-09 2012-12-20 シービーティ・デベロップメント・リミテッド 医薬として使用するための組合せ製剤
HUE034866T2 (hu) 2010-01-15 2018-03-28 Inst Nat Sante Rech Med NKCC inhibitorok az autizmus kezelésére
US20130123124A1 (en) * 2010-03-12 2013-05-16 Children's Medical Center Corporation Methods and compositions for characterizing autism spectrum disorder based on gene expression patterns
WO2015023830A1 (en) * 2013-08-14 2015-02-19 Stc.Unm Treatment and prevention of stroke and other neurological disorders
AU2014324608B2 (en) * 2013-09-27 2019-08-08 Justin SHER Nutraceutical compositon for PDE4 inhibition, enhanced dopamine metabolism and long term potentiation
CA3023014C (en) * 2017-11-06 2023-09-26 Stalicla Sa Pharmaceutical composition for treatment of autism
CA3118790A1 (en) * 2018-11-06 2020-05-14 Stalicla Sa Metabolic profiling for the diagnosis of a subset of idiopathic autism spectrum disorder patients, asd phenotype 1

Also Published As

Publication number Publication date
JP2020059711A (ja) 2020-04-16
CN119303086A (zh) 2025-01-14
JP2019089755A (ja) 2019-06-13
CA3023014A1 (en) 2019-05-06
US20210154177A1 (en) 2021-05-27
US20190134011A1 (en) 2019-05-09
US10940140B2 (en) 2021-03-09
US11439627B2 (en) 2022-09-13
KR20190051853A (ko) 2019-05-15
JP7012054B2 (ja) 2022-02-10
EP3984555A1 (en) 2022-04-20
ES2908863T3 (es) 2022-05-04
BR102018072757A2 (pt) 2019-06-04
EP3498297C0 (en) 2023-06-21
AU2018260807A1 (en) 2019-05-23
EP3785733B1 (en) 2022-01-05
KR102372678B1 (ko) 2022-03-10
EP3785733A1 (en) 2021-03-03
AU2018260807B2 (en) 2020-07-09
EP3498297B1 (en) 2023-06-21
DK3785733T3 (da) 2022-04-11
EP3498297A1 (en) 2019-06-19
CN109821019A (zh) 2019-05-31
CA3023014C (en) 2023-09-26
US20210145803A1 (en) 2021-05-20
ES2962383T3 (es) 2024-03-18

Similar Documents

Publication Publication Date Title
EP3498297C0 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF AUTISM
ZA202004025B (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
HUE054316T2 (hu) Gyógyászati készítmény rák kezelésére
IL261824A (en) Pharmaceutical combinations for cancer treatment
IL256175A (en) Using exosomes to treat the disease
IL255509B (en) Compounds as modulators of ccr2, pharmaceutical preparations containing them and their use in the treatment of diseases
SMT201900172T1 (it) Ammino triazoli sostituiti utili come inibitori della chitinasi umana
ZA201807125B (en) Pharmaceutical composition of dapagliflozin
SI3302573T1 (sl) Sestavek za zdravljenje možganskih lezij
PL3424499T3 (pl) Kompozycja farmaceutyczna do leczenia bólu neuropatycznego
IL275525A (en) A pharmaceutical preparation for the treatment of cancer
IL261278A (en) Pharmaceutical compositions for the treatment of cancer
ZA201803320B (en) Pharmaceutical compositions for treating pain
GB201518456D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory, autoimmune and/or proliferative diseases
ZA201804588B (en) Pharmaceutical formulations for the treatment of diabetes
IL252774A0 (en) A pharmaceutical preparation for the treatment of fungus
EP3253379A4 (en) Pharmaceutical composition for the treatment of obesity
IL257689A (en) Pharmacological preparations and methods for the treatment of diseases associated with hypoxia
PT3785733T (pt) Composição farmacêutica para o tratamento do autismo
PL3415142T3 (pl) Kompozycja do leczenia zapalenia brzegów powiek zawierająca terpinen-4-ol
PL3164110T3 (pl) Kompozycje farmaceutyczne do leczenia łuszczycy
GB201714241D0 (en) Pharmaceutical compositions for the treatment of proteinopathies
GB201814764D0 (en) Pharmaceutical compositions for the treatment of proteinopathies
GB201719584D0 (en) Pharmaceutical compositions for the treatment of cancer
ZA201705781B (en) Pharmaceutical compositions for the treatment of bacterial infections